Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TEM.

← Back to Free Index

TEM

Analysis as of: 2025-12-27

Tempus AI, Inc.

Tempus builds AI-enabled precision medicine products spanning clinical diagnostics, multimodal data products for biopharma, and software to support clinical care and trial execution.

ai biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

Diagnostics-to-data flywheel, now testing workflow monetization

The growth case depends on a mix shift from testing into recurring data and workflow software, sustaining a premium valuation while diagnostics multiples compress. Execution is credible, but reimbursement and distribution friction remain the gating risks.

Analysis

Thesis

Tempus can convert regulated diagnostics throughput into a compounding data + clinical-workflow platform: as AI commoditizes cognition, durable value shifts to trusted distribution, governed datasets, and auditability—driving a mix shift from lab revenue to higher-multiple software/data by 2030.

Last Economy Alignment

AI makes clinical “thinking work” cheaper; Tempus is positioned to monetize scarce trust, distribution into care workflows, and governed multimodal data rights.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied Multiple (to 2030)

2.4x (from 5 most recent analyses)

Reasoning

The upside is a non-linear mix shift: diagnostics stays a high-velocity data-creation engine, while trials software, pathology AI, and workflow-embedded agents increase repeat monetization per patient record. If Tempus keeps landing multi-year biopharma collaborations and proves higher-margin, more recurring software/data revenue, it can sustain a premium platform valuation even as pure testing multiples compress.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is that Tempus remains viewed as a capital-intensive diagnostics/services roll-up: reimbursement pressure caps gross profit, software/data fails to become sufficiently recurring, and workflow incumbents (or bundled offerings) win distribution—forcing multiple compression before Tempus reaches scaled profitability.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Dec 22, 2025: Canaccord maintained a Strong Buy but reduced its price target (per compiled analyst history).
Dec 23–26, 2025: Technical/relative-strength commentary noted improving price strength vs peers, but no clear breakout setup.
No new earnings release since Nov 4, 2025; narrative still anchored to raised 2025 revenue guidance and early EBITDA inflection.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

12-Month Price Target

$77.86

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case